Published in J Clin Oncol on June 01, 2001
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. J Natl Cancer Inst (2013) 3.46
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell (2010) 1.71
Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol (2011) 1.48
Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer (2010) 1.46
Management of paraproteinaemia. Postgrad Med J (2007) 1.08
Pathophysiology of cancer-related fatigue. Clin J Oncol Nurs (2008) 1.05
Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer (2003) 1.04
Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol (2006) 1.01
Clinical evaluation of once-weekly and three-times-weekly dosings of epoetin alfa in chemotherapy patients: problems of study design and interpretation. J Clin Oncol (2002) 0.98
Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest (2014) 0.94
Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial. Br J Cancer (2006) 0.93
Pharmacodynamic model for chemotherapy-induced anemia in rats. Cancer Chemother Pharmacol (2007) 0.93
Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer (2002) 0.92
A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia. Support Care Cancer (2014) 0.92
Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data. Br J Cancer (2014) 0.90
Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer (2002) 0.88
Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study. Drug Des Devel Ther (2013) 0.87
A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer (2003) 0.86
Treatment-induced anaemia and its potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer (2002) 0.85
Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol (2006) 0.84
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. Oncologist (2010) 0.84
More concern about transfusion requirement when evaluating quality of life in anemic patients. J Clin Oncol (2002) 0.83
Epoetin beta for the treatment of chemotherapy-induced anemia: an update. Onco Targets Ther (2015) 0.83
Iron metabolism and iron supplementation in cancer patients. Wien Klin Wochenschr (2015) 0.83
Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey. Wien Klin Wochenschr (2004) 0.82
Impact of safety concerns and regulatory changes on the usage of erythropoiesis-stimulating agents and RBC transfusions. Oncologist (2010) 0.81
Erythropoiesis-stimulating agents: benefits and risks in supportive care of cancer. Curr Oncol (2008) 0.80
Quality of life and supportive care in multiple myeloma. Turk J Haematol (2013) 0.80
Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: a prospective, observational study. Support Care Cancer (2013) 0.78
Bloodless cancer treatment results of patients who do not want blood transfusion: single center experience of 77 cases. Support Care Cancer (2009) 0.78
Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. Cancer (2008) 0.78
Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy. Support Care Cancer (2006) 0.77
The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nurs (2003) 0.77
Impact of changes in reimbursement policies and institutional practice algorithm for utilization of erythropoietic-stimulating agents on treatment patterns and costs in anemic lymphoma patients. Support Care Cancer (2010) 0.77
Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. Int J Clin Oncol (2013) 0.76
Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline. Support Care Cancer (2004) 0.76
Correlation between variation in quality of life and change in hemoglobin level after treatment with epoetin alfa 40,000 IU administered once-weekly. Support Care Cancer (2007) 0.76
Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial. BMC Cancer (2010) 0.76
Darbepoetin versus epoetin alfa for the correction of anemia in cancer patients receiving radiotherapy or chemoradiotherapy treatment. Clin Med Oncol (2008) 0.75
Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia. Ther Clin Risk Manag (2007) 0.75
The efficacy of recombinant human erythropoietin in treatment chemotherapy induced anemia in children diagnosed with a solid cancer. Iran J Ped Hematol Oncol (2014) 0.75
Managing anemia in lymphoma and multiple myeloma. Ther Clin Risk Manag (2008) 0.75
Development and evaluation of a cancer-related fatigue patient education program: protocol of a randomized controlled trial. BMC Nurs (2008) 0.75
Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy. J Clin Oncol (2002) 0.75
Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia. Cancer Med (2016) 0.75
Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. Support Care Cancer (2004) 0.75
An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy. Support Care Cancer (2007) 0.75
The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer (1999) 7.87
Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain (1983) 6.46
When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain (1995) 5.97
Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol (2010) 5.96
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med (1999) 5.84
Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med (1977) 4.91
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. N Engl J Med (2000) 4.54
Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res (1977) 4.02
Drugs five years later. Cisplatin. Ann Intern Med (1984) 3.69
Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med (1987) 3.52
Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med (1993) 3.25
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol (1991) 3.01
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol (1992) 2.90
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst (1997) 2.80
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2000) 2.73
Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med (1990) 2.64
Effect of delay in radiation in the combined modality treatment of breast cancer. Int J Radiat Oncol Biol Phys (1993) 2.42
Minority cancer patients and their providers: pain management attitudes and practice. Cancer (2000) 2.13
No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 2.11
Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res (1994) 2.10
The prevalence and severity of pain in cancer. Cancer (1982) 2.07
1st International consensus guidelines for advanced breast cancer (ABC 1). Breast (2012) 1.96
Combination chemotherapy in disseminated testicular cancer: the Indiana University experience. Semin Oncol (1979) 1.91
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1998) 1.91
The Chinese version of the Brief Pain Inventory (BPI-C): its development and use in a study of cancer pain. Pain (1996) 1.89
Late relapse of testicular cancer. J Clin Oncol (1995) 1.87
The development of non-germ cell malignancies within germ cell tumors. A clinicopathologic study of 11 cases. Cancer (1984) 1.85
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol (1992) 1.84
Chemotherapy of disseminated testicular cancer. A random prospective study. Cancer (1980) 1.79
Multicentre study of cancer pain and its treatment in France. BMJ (1995) 1.78
High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol (1996) 1.77
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer (2006) 1.77
Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. Chest (1991) 1.72
Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol (1998) 1.72
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol (1997) 1.70
Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol (1997) 1.70
Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol (1989) 1.68
Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res (2001) 1.64
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol (1999) 1.63
High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol (1993) 1.61
Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol (1999) 1.59
Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol (1990) 1.57
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med (1979) 1.57
Validation of the German version of the Brief Pain Inventory. J Pain Symptom Manage (1999) 1.56
Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med (1993) 1.55
Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol (1994) 1.51
Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol (1993) 1.51
Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol (1988) 1.49
Metastatic patterns of choroidal melanoma. Cancer (1974) 1.45
Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. Ann Intern Med (1978) 1.44
Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience. Eur J Cancer (2000) 1.42
Hematologic malignancies associated with primary mediastinal germ-cell tumors. Ann Intern Med (1985) 1.41
Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol (1994) 1.39
A brief cancer pain assessment tool in Japanese: the utility of the Japanese Brief Pain Inventory--BPI-J. J Pain Symptom Manage (1998) 1.38
Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group. Cancer (1997) 1.38
Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res (1981) 1.37
Improved chemotherapy in disseminated testicular cancer. J Urol (1977) 1.37
18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol (2001) 1.35
Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer (1978) 1.35
Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer (1999) 1.33
Fertility after chemotherapy for testicular cancer. J Clin Oncol (1983) 1.32
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med (1987) 1.30
Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol (1993) 1.29
Epidermal growth factor stimulation of human breast cancer cells in culture. Cancer Res (1980) 1.29
Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol (1997) 1.26
The relationship of neuropsychological impairment to other indices of severity of head injury. Scand J Rehabil Med (1972) 1.25
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res (1974) 1.25
Testicular cancer: the quest continues. J Natl Cancer Inst (1988) 1.25
Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol (2008) 1.24
Specialized paranodal and interparanodal glial-axonal junctions in the peripheral and central nervous system: a freeze-etching study. Brain Res (1973) 1.23
Germ cell tumor associated primitive neuroectodermal tumors. J Urol (2001) 1.23
A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain (1996) 1.22
The assessment of cancer pain in north India: the validation of the Hindi Brief Pain Inventory--BPI-H. J Pain Symptom Manage (1999) 1.22
Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol (1991) 1.22
Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol (1988) 1.22
The role of maintenance therapy in disseminated testicular cancer. N Engl J Med (1981) 1.22
Late relapse of clinical stage I testicular cancer. J Urol (1995) 1.17
Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant (2007) 1.17
Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol (1995) 1.16
Involving family members in cancer care: focus group considerations of patients and oncological providers. Psychooncology (2000) 1.15
Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors. Cancer (2000) 1.15
Validation of the Brief Pain Inventory in a Taiwanese population. J Pain Symptom Manage (1999) 1.12
Long-term results in combined-modality treatment of small cell carcinoma of the lung. Semin Oncol (1978) 1.12
The effects of induced mood on laboratory pain. Pain (1991) 1.12
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol (1993) 1.12
Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer (1981) 1.11
Klinefelter's syndrome associated with mediastinal germ cell neoplasms. J Clin Oncol (1987) 1.10
VP-16-213 salvage therapy for refractory germinal neoplasms. Cancer (1980) 1.10
A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol (1991) 1.10
Symptom instability and thermoregulation in multiple sclerosis. Neurology (1972) 1.10
Is retroperitoneal lymph node dissection necessary for adult paratesticular rhabdomyosarcoma? J Urol (1998) 1.09
Undertreatment of cancer pain in elderly patients. JAMA (1998) 1.09
Small cell lung cancer: progress and perspectives. Semin Oncol (1978) 1.09
The role of cis-platinum in solid-tumor therapy. N Engl J Med (1979) 1.08
Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. J Clin Oncol (1985) 1.08